Emerging challenges in pharmacotherapy research on attention-deficit hyperactivity disorder—outcome measures beyond symptom control and clinical trials
- Andre Carvalho
- Investigação
- Acessos: 42
Prof Ian C K Wong, PhD1, Prof Tobias Banaschewski, MD2, Prof Jan Buitelaar, MD3, Samuele Cortese, MD4, Döpfner Manfred Döpfner, PhD5, Prof Emily Simonoff, MD6, Prof David Coghill, MD7.
on behalf of the European ADHD Guidelines Group
- 1
- Affiliations
Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong Special Administrative Region, China
Research Department of Practice and Policy, University College London, School of Pharmacy, London, UK - 2
- Affiliations
Department of Child and Adolescent Psychiatry and Psychotherapy, Medical Faculty Mannheim, Central Institute of Mental Health, University of Heidelberg, Mannheim, Germany - 3
- Affiliations
Department of Cognitive Neuroscience, Donders Institute for Brain, Cognition and Behaviour, Radboud University Nijmegen Medical Centre, and Karakter Child and Adolescent Psychiatry University Centre, Nijmegen, Netherlands - 4
- Affiliations
Centre for Innovation in Mental Health, School of Psychology and Clinical and Experimental Sciences (CNS and Psychiatry), Faculty of Medicine, University of Southampton, Southampton, UK - 5
- Affiliations
Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Medical Faculty of the University of Cologne, Cologne, Germany - 6
- Affiliations
Department of Child and Adolescent Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London, and National Institute for Health Research Maudsley Biomedical Research Centre for Mental Health, London, UK - 7
- Affiliations
Departments of Paediatrics and Psychiatry, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, and Murdoch Children's Research Institute, Melbourne, VIC, Australia
Junho 2019